Gentris, a subsidiary of Cancer Genetics, Inc., is a global provider of pharmacogenomic testing and biorepository services. As pioneers in the field, Gentris helps pharmaceutical companies and clinical research organizations effectively integrate pharmacogenomics into their drug development programs to deliver safer, more effective compounds to the market more quickly. With better characterization of patient populations, pharmacogenomics can help reduce drug failure rates by enabling drug companies to modify patients’ exposure to drugs based on their genomic drug-response profile. This ensures that the right drugs reach the right patients at the right doses, and provides optimal benefits for their pharmacogenomic profile.